MORE►
Secretome Therapeutics
Secretome Therapeutics’ leadership team includes, from left: David Chapman, senior vice president of operations; Karin Lucas, Ph.D., vice president of medical affairs; Maggie Loeffler, CPA, vice president of finance and administration; and Marshelle Smith, M.D., chief development officer. [Photos: Secretome Therapeutics]
Secretome Therapeutics Builds Out Rare Disease Leadership Team
by Sandra Engelland | Aug 4, 2026
The Plano company’s lead candidate uses neonatal cardiac progenitor cells to target the heart complications of Duchenne muscular dystrophy.
by Sandra Engelland |
May 28, 2026
The financing from Boston's RA Capital Management will support company operations and the continued development of Secretome’s pipeline of innovative treatments, including STM-01, an nCPC-derived therapy in development for treating Duchenne muscular dystrophy, which has had few therapeutic options.
MORE►
by Lance Murray |
Apr 23, 2025
Michelle Smith Warren, MD, is a highly experienced pharmaceutical executive with more than two decades of leadership in clinical development, translational medicine, and regulatory strategy across multiple therapeutic areas, including cell therapy, immunology, cardiovascular, and rare diseases, Secretome said.
MORE►
by Lance Murray |
Dec 9, 2024
Baltimore-based Secretome—which has a presence at BioLabs at Pegasus Park in Dallas and offices in Plano—said the financing will enable it to initiate clinical trials for its lead asset, STM-01, and further advance its drug development pipeline.
MORE►
Form Bio, named as one of eight Rising Stars to be honored at iC3 2023, announced its launch at the last year's summit. [Photo: John Davidson/Form Bio]
BioNTX iC3 Summit to Fuel North Texas Life Science Ecosystem, Honor 8 Rising Stars
by Quincy Preston | Sep 14, 2023
The North Texas bioscience organization, a driving force for growth in the regional ecosystem, will convene leaders at its flagship conference to catalyze industry opportunities, spotlight emerging companies, and make connections.
See who made this year's Rising Stars list—and how you can attend the summit.
See who made this year's Rising Stars list—and how you can attend the summit.
MORE►
by Lance Murray |
Aug 3, 2023
Dallas-based Secretome Therapeutics announced that Deepa Prasad has been appointed chief financial officer of the biotechnology company, which develops first-in-class therapeutics derived from neonatal mesenchymal stem cells for the treatment of underserved diseases.
“Deepa brings a wealth of knowledge through her combination of investment banking, operations, and venture capital experience in the life science industry,” Vinny Jindal, president and chief executive officer of Secretome Therapeutics, said in a statement....
MORE►
by Lance Murray |
Jul 20, 2023
Secretome Therapeutics, a Dallas-based biotechnology company developing first-in-class therapeutics from neonatal mesenchymal stem cells, has appointed Margot Connor to its board of directors and announced the appointment of its clinical advisory board composed of world-class clinicians and researchers in the field of heart failure.
“I have been fortunate to be part of the stem cell-based therapy evolution, and I believe secretomes are a true breakthrough in this extraordinary field,” Connor said in a statement....
MORE►
